



## Codexis to Present at 2013 BIO International Convention

April 22, 2013

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Apr. 22, 2013-- Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for pharmaceutical, biofuel and chemical production, announced today that Gjalt Huisman, Ph.D., Vice President, Pharmaceutical R&D at Codexis, will present at the 2013 BIO International Convention in Chicago, IL, on Tuesday, April 23, 2013. Dr. Huisman will present an overview of the company's application of its CodeEvolver® directed evolution technology platform in the field of enzyme therapeutics.

"Codexis' technology has revolutionized the manufacture of pharmaceuticals and is currently used in the production of some of the world's bestselling drugs. We are now applying our advanced technology to generate new and improved biologic therapeutics," said Dr. Huisman. "Now that we have established the core value that our technology brings, we are excited to apply our technology platform as the operating system to generate new and improved therapeutic enzymes in a broad array of applications. We may evaluate opportunities in a number of therapeutics areas, such as enzyme replacement, metabolic pool depletion, celiac disease and antibody therapies."

Event: 2013 BIO International Convention's BIO Business Forum

Date: Tuesday, April 23, 2013

Time: 8:15 a.m. Central Time

Location: Chicago Bulls Room; McCormick Place Convention Center; Chicago, IL

### About Codexis, Inc.

Codexis, Inc. engineers enzymes for pharmaceutical, biofuel and chemical production. Codexis' proven technology enables scale-up and implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable process development – from research to manufacturing. For more information, see [www.codexis.com](http://www.codexis.com).

### Forward-Looking Statements

This press release contains forward-looking statements relating to Codexis' ability to deploy its technology platform to generate new and improved therapeutic enzymes. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis' control and that could materially affect actual results. Factors that could materially affect actual results include Codexis' need for substantial additional capital in the future in order to expand its business; Codexis' dependence on its collaborators; potential adverse effects to Codexis' business if its customers' pharmaceutical products are not received well in the markets; Codexis' ability to develop and commercialize new products for the pharmaceutical markets; and Codexis' ability to deploy its technology platform in new adjacent market spaces. Additional factors that could materially affect actual results can be found in Codexis' Annual Report on Form 10-K for the period ended December 31, 2012 filed with the Securities and Exchange Commission on April 2, 2013, including under the caption "Risk Factors." Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Source: Codexis, Inc.

For Codexis, Inc.

Media

Jemma Connor, +44 161 359 3255

[jemma.connor@notchcommunications.co.uk](mailto:jemma.connor@notchcommunications.co.uk)

or

Investors

Paul Cox, 212-362-1200

[ir@codexis.com](mailto:ir@codexis.com)